A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
AJ Armstrong, T Shen, S Halabi, G Kemeny… - Clinical genitourinary …, 2013 - Elsevier
Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
A Schayowitz, G Sabnis, O Goloubeva… - British journal of …, 2010 - nature.com
Background: To determine the mechanisms associated with loss of androgen dependency
and disease progression in prostate cancer (PCa), we investigated the relationship between …
and disease progression in prostate cancer (PCa), we investigated the relationship between …
Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer
RJ Macfarlane, C Hovens, NM Corcoran… - Prostate Cancer: A …, 2013 - Springer
This chapter serves as a review of the current standard systemic treatment options available
for metastatic castration resistant prostate cancer as well as the concepts and rationale …
for metastatic castration resistant prostate cancer as well as the concepts and rationale …